Integrated 5-HT 2A –TrkB and G protein signaling in serotonergic psychedelic responses
Marco Taddei-Tardón, Lidia Medina-Rodríguez, Jessica L. Maltman, Sarah Hudson, Sritanvi Potukanuma, Javier Hidalgo Jiménez, Sandra M. Martin-Guerrero, Javier González-Maeso, Juan F López-Giménez
bioRxiv (Cold Spring Harbor Laboratory) March 23, 2026 DOI: 10.64898/2026.03.19.712961 via OpenAlex
Summary
AI-generated from the abstractSerotonergic psychedelics, including tryptamines, phenethylamines, and ergolines, promote structural and transcriptional changes in neurons through an integrated signaling network involving the 5-HT2A receptor and TrkB. Using a neural stem cell-derived model, the study shows that TrkB silencing blocks dendritogenesis induced by psychedelics, ketamine, and TrkB agonists, while 5-HT2A silencing selectively impairs psychedelic-induced plasticity. Most compounds increase synaptogenesis and immediate-early gene expression, though psilocin and the phenethylamines DOI and Ariadne show ligand-specific differences. Lactate production, dependent on 5-HT2A and both Gq/11 and Gi/o protein signaling, also occurs. These results establish a platform for dissecting psychedelic action.
Study at a glance
| Characteristics | In vitro study Peer reviewed |
|---|---|
| Population | Neural stem cell-derived in vitro model differentiating into neuronal and glial lineages |
| Interventions | phenethylamines ketamine TrkB agonists |
| Topics | Neuroplasticity Serotonin |
| Keywords | Phenethylamines Gene silencing G protein-coupled receptor |
| Key finding | Serotonergic psychedelics recruit an integrated 5-HT2A-TrkB signaling network that drives dendritogenesis, synaptogenesis, gene expression, and lactate production, with ligand-specific differences and dependence on both Gq/11 and Gi/o protein pathways. |
Abstract
Abstract Serotonergic psychedelics have attracted considerable interest as promising therapeutic agents. However, the molecular mechanisms linking their acute hallucinogenic-like effects to longer-lasting neuroplastic responses remain incompletely understood, partly because of the scarcity of native neural models suitable for mechanistic studies. Here, we developed a neural stem cell-derived in vitro model capable of differentiating into neuronal and glial lineages and, after characterization, used it to investigate the molecular pharmacology of serotonergic psychedelics. A panel comprising tryptamines, phenethylamines and ergolines, including psychedelic compounds and selected non-psychedelic analogues, was evaluated alongside ketamine and TrkB agonists. Endpoints included dendritogenesis, synaptogenesis, immediate-early gene induction, BDNF expression and lactate production. TrkB silencing abolished dendritogenic responses to serotonergic psychedelics, ketamine and TrkB agonists, whereas 5-HT 2A receptor silencing selectively impaired serotonergic psychedelic-induced plasticity and altered TrkB-dependent responses. Most serotonergic compounds also increased synaptogenesis and induced c-Fos and Egr-2 expression, although ligand-specific differences were evident, particularly for psilocin and the phenethylamines DOI and Ariadne. Uncoupling of G q/11 or G i/o protein-dependent signaling differentially modified neuroplastic and transcriptional responses, indicating a ligand and endpoint dependent contribution of both pathways. Serotonergic psychedelics further induced a 5-HT 2A receptor dependent lactate response that was generally sensitive to disruption of either G q/11 or G i/o protein coupling. Taken together, these findings support a model in which serotonergic psychedelics recruit an integrated 5-HT 2A -TrkB signaling network with distinct structural, transcriptional and metabolic outputs, and establish this neural stem cell-derived system as a valuable platform for screening and dissecting the signaling basis of psychedelic action.